Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:02 26/06/2024 am IST			5-day change	1st Jan Change
41.04 ^USD	-2.36%		-6.19%	-8.34%

21/06	Qiagen Seeks M&A	CI
21/06	Transcript : Qiagen N.V. - Shareholder/Analyst Call

Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024

June 07, 2024 at 01:35 am IST

Qiagen N.V. reaffirmed earnings guidance for the second quarter of 2024. For the quarter, the company expected net sales of at least $495 million at constant exchange rates (CER).

Latest news about Qiagen N.V.

Qiagen Seeks M&A	21/06	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	21/06
Sartorius on the downswing again - low since 2020 is approaching	19/06	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	19/06	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	18/06	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	18/06	MT
QIAGEN NV : Gets a Neutral rating from UBS	18/06	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	18/06	ZD
QIAGEN NV : Berenberg remains its Buy rating	18/06	ZD
Frankfurt shares close: Dax recovers	17/06	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	17/06
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	17/06	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	17/06	MT
Qiagen eyes sales growth of 7% per year until 2028	17/06	RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret	14/06	CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook	07/06	MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System	07/06	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024	07/06	CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe	06/06	CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care	03/06	CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	31/05	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	31/05	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	31/05	CI
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine	30/05	CI
QIAGEN NV : Berenberg maintains a Buy rating	21/05	ZD

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

12:30pm - Stifel European Healthcare Summit

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 07:02 pm IST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.04 USD

Average target price

50.39 USD

Spread / Average Target

+22.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-8.34%	910.46Cr
MODERNA, INC.	+38.36%	5.27TCr
LONZA GROUP AG	+38.79%	3.9TCr
IQVIA HOLDINGS INC.	-8.63%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	3.04TCr
CELLTRION, INC.	-11.17%	2.64TCr
ICON PUBLIC LIMITED COMPANY	+11.44%	2.61TCr
UNITED THERAPEUTICS CORPORATION	+45.09%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.93%	1.26TCr
BIO-TECHNE CORPORATION	-5.30%	1.15TCr

Other Biotechnology & Medical Research

Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024

Latest news about Qiagen N.V.

Chart Qiagen N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Qiagen N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research